secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2026-08-13T20:08:48+00:00
Accession:  0001193125-26-349170
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Q2 net loss $31.6M; cash $88.8M; Phase 3 kidney trial on track
---------------------------------------------------------------------

- Cash $88.8M at June 30, 2026 vs $133.3M at Dec 31, 2025; expected to fund ops into Q2 2027.
- Q2 net loss $31.6M ($0.27/share) vs $11.2M ($0.13) prior year; ex-warrant changes, loss $22.0M vs $23.5M.
- FDA End-of-Phase 2 meeting supports Phase 3 kidney transplant trial of tegoprubart; ~600 patients, late 2026 start.
- BESTOW 18-month data: eGFR ~12 mL/min higher vs tacrolimus (74 vs 61); no BPAR after 6 months in tegoprubart arm.
- Islet cell study: all 12 T1D patients insulin-independent, mean HbA1c ~5.4%; Natera Prospera partnership for Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/0001193125-26-349170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/eldn-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer